Please login to the form below

Not currently logged in
Email:
Password:

Aragon Pharma

This page shows the latest Aragon Pharma news and features for those working in and with pharma, biotech and healthcare.

J&J’s Erleada first US drug for non-metastatic prostate cancer

J&J’s Erleada first US drug for non-metastatic prostate cancer

J&J acquired Erleada when it took over Aragon Pharma in 2013 in a deal valued at $1bn.

Latest news

  • J&J completes Aragon deal as Seragon is born J&J completes Aragon deal as Seragon is born

    The deal secures a promising new prostate cancer therapy for the pharma major in the form of Aragon's ARN-509, a second generation androgen receptor signalling inhibitor which has reached ... Seragon spun out. The closure of the deal also sees the

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...

Infographics